http://www.fpnotebook.com/
OxcarbazepineAka: Trileptal
- Indications
- Adverse Effects: Dose related
- Adverse Effects: Other
- Hyponatremia
- Cardiac arrhythmia
- Dosing: Adults (includes elderly)
- Initial: 300 mg PO bid
- Increase by 600 mg/day weekly
- Target dose: 600 mg PO bid
oxcarbazepine (C0069751) | |
|---|---|
| Definition (NCI) | A dibenzazepine carboxamide derivative with an anticonvulsant property. As a prodrug, oxcarbazepine is converted to its active metabolite, 10-monohydroxy. Although the mechanism of action has not been fully elucidated, electrophysiological studies indicate this agent blocks voltage-gated sodium channels, thereby stabilizing hyper-excited neural membranes, inhibiting repetitive neuronal firing, and decreasing the propagation of synaptic impulses. |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C036006 |
| English | oxcarbazepine, OXCARBAZEPINE PREPARATION |
| Spanish | oxcarbacepina, oxcarbazepina |
| Parent Concepts | Anticonvulsants (C0003286), Carbamazepine (C0006949), Carbazepine antiepileptic (C0360123), Carbamazepine and derivatives (C1445633), Duplicate concept (C1274013), Sodium Channel Blockers (C0872271) |
| Sources | LNC, MSH, MTHSPL, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Trileptal (C0876196) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C036006 |
| English | Novartis brand of oxcarbazepine, Trileptal |
| Sources | MSH, MTH, NCI, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
